Description

As of mid-2026, the Adderall shortage that began in October 2022 remains active, affecting both immediate-release and extended-release amphetamine formulations. This guide explains the current status, which formulations are hardest to find, and practical alternatives your provider may recommend.

Is the Adderall Shortage Still Happening in 2026?

TLDR

The Adderall shortage started in October 2022 and is still active as of 2026, according to ASHP and FDA shortage listings. DEA quota increases in late 2025 and early 2026 improved supply somewhat, but higher-dose formulations remain inconsistent. If your pharmacy is out of stock, there are clinically comparable alternatives your provider can prescribe.

Yes. As of June 2026, both immediate-release (IR) and extended-release (XR) amphetamine mixed salts remain on the American Society of Health-System Pharmacists (ASHP) shortage list. The FDA's original shortage notice from October 2022 also remains active.

The shortage has now lasted more than three years and has affected multiple manufacturers, formulations, and dosage strengths.

Why Did the Adderall Shortage Start?

Several factors combined to create the shortage:

• Increased demand: ADHD diagnoses rose sharply during and after the pandemic, driven in part by expanded telehealth access.
• DEA production quotas: The DEA sets annual manufacturing limits for Schedule II stimulants. When demand outpaced quotas, manufacturers could not keep up.
• Supply chain disruptions: COVID-19 affected active pharmaceutical ingredient (API) sourcing from overseas suppliers.
• Single-source dependency: Several generics relied on a small number of API manufacturers, creating bottlenecks.

Which Adderall Formulations Are Hardest to Find?

Higher-dose formulations are the most affected, particularly:

• Adderall XR 15 mg, 20 mg, and 25 mg (amphetamine mixed salts ER)
• Adderall IR 20 mg and 30 mg
• Amneal's extended-release 10 mg and 15 mg remain listed as active shortage items as of August 2025 per the ASHP.

Lower-dose formulations and brand-name Adderall may be easier to source, though availability varies by region and pharmacy.

When Will the Adderall Shortage End?

There is no confirmed end date. The DEA increased manufacturing quotas for amphetamine salts in late 2025 and again in early 2026, which improved supply overall. However, the shortage has not been officially resolved.

Higher-dose formulations are typically the last to normalize because manufacturers prioritize the highest-volume items first. For many patients, intermittent shortages may continue into late 2026.

What Are the Best Alternatives to Adderall?

If your pharmacy cannot fill your prescription, your provider may consider:

Amphetamine-Based Alternatives

• Adzenys XR-ODT (amphetamine XR orally disintegrating tablet): The closest pharmacological equivalent to Adderall XR. Often the top substitute recommended by prescribers when Adderall XR is unavailable.
• Dyanavel XR: Extended-release amphetamine oral suspension.
• Evekeo: Mixed amphetamine salts with a slightly different ratio.

Manufacturer discounts and coupons are often available for these newer branded alternatives.

Methylphenidate-Based Alternatives

Methylphenidate and amphetamine act on the same pathways through different mechanisms. Methylphenidate-based medications — Ritalin, Concerta, Focalin, Quillichew, Jornay PM — have been less affected by the shortage and are a common interim option.

Non-Stimulant Options

For patients who cannot access stimulants or prefer a different approach:

• Strattera (atomoxetine): Non-stimulant, full-day coverage, no controlled substance restrictions
• Qelbree (viloxazine): Newer non-stimulant approved for adults
• Wellbutrin (bupropion): Off-label for ADHD, commonly used

Can I Get Adderall Through Telehealth in 2026?

Yes. DEA telemedicine flexibilities, currently extended through December 31, 2026, allow DEA-registered providers to prescribe Schedule II stimulants like Adderall via video telehealth without a prior in-person visit, provided all clinical requirements are met.

This means a licensed provider at a platform like Klarity Health can evaluate you for ADHD and, when clinically appropriate, prescribe stimulant medication. Your local pharmacy still needs to have the medication in stock.

What Should I Do If My Pharmacy Is Out of Stock?

1. Call ahead: Ask the pharmacy to check their system and when they expect restocking before making the trip.
2. Try independent pharmacies: Chain pharmacies often have lower inventory than local independents.
3. Ask your pharmacist about equivalents: Pharmacists can contact your prescriber directly to authorize a substitution.
4. Talk to your prescriber proactively: A provider can prescribe an alternative formulation or brand. Do not wait until you run out.
5. Check nearby pharmacies: GoodRx has a drug availability tool that shows stock across pharmacies by zip code.

Managing ADHD Through the Shortage

If you have been managing symptoms without consistent medication access, a licensed provider can help review your options. They may adjust your formulation to something more available, recommend a non-stimulant as a bridge or supplement, or work with you on structured strategies to maintain function.

Klarity Health connects you with 2,000+ licensed psychiatric providers for online ADHD evaluations. If you are struggling to manage your ADHD during the shortage, a provider can review your situation and discuss what options may be appropriate for your case.

See if you may qualify at helloklarity.com

This content is for educational purposes and is not a substitute for professional medical advice. Treatment decisions are made by licensed healthcare providers based on individual clinical factors.